Novo Nordisk’s obesity feast lacks a second course
The $174 bln weight loss pioneer plans to expand in new treatments. Yet a promised extra $23 bln of revenue by 2035 will barely offset the loss of sales as its core Wegovy franchise comes off …
The $174 bln weight loss pioneer plans to expand in new treatments. Yet a promised extra $23 bln of revenue by 2035 will barely offset the loss of sales as its core Wegovy franchise comes off …